六連板的博暉創新(300318.SZ):靜注人免疫球蛋白(pH4)、人凝血酶原複合物產品取得藥品註冊證書
格隆匯 8 月 5日丨連續6個漲停的博暉創新(300318.SZ)發佈股價異動公告稱,公司控股孫公司中科生物製藥股份有限公司(“中科生物”)與成都柏奧特克生物科技股份有限公司(“柏奧特克”)於2020年1月簽訂《項目合作合同》,聯合申報凍幹人用狂犬病疫苗(無血清Vero細胞)產品。公司於近日從柏奧特克處獲悉該產品收到國家藥品監督管理局核准簽發《藥物臨牀試驗批准通知書》。該產品臨牀試驗、審評和審批的結果以及時間都具有一定的不確定性。
根據合同約定,該產品的知識產權由柏奧特克持有;且產品上市後10年內,中科生物只獲得該產品每年度生產經營税後10%淨利潤,利益分配佔比較小。同時公司持有河北大安製藥有限公司(“河北大安”)40.14%股權,河北大安持有中科生物72%股權,若該產品成功上市,歸屬於上市公司的利潤也較小。上述產品臨牀試驗批准通知書的取得不會對公司近期業績產生重大影響。敬請廣大投資者謹慎決策,注意投資風險。上述事項具體情況詳見公司於2020年7月24日披露的相關公告。
公司控股子公司河北大安研發的靜注人免疫球蛋白(pH4)、人凝血酶原複合物產品於近日收到國家藥品監督管理局核准簽發《藥品註冊證書》。上述產品註冊證的取得對河北大安提高血漿利用效率及申請設立新的單採血漿站具有重要的意義。但鑑於血液製品的生產和銷售特點,預計不會對河北大安及公司本年度業績產生重大影響。敬請廣大投資者謹慎決策,注意投資風險。上述事項具體情況詳見公司於2020年7月28日、2020年8月1日披露的相關公告。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.